Arca
Skip to content
Tools
Tools

POL: Human immunodeficiency virus type 1 integrase

Protein in Human immunodeficiency virus 1 that 7 drugs act on.

  • Drugs that act on it: 7
  • Approved: 5
  • In phases 1 to 3: 2
  • Sponsors: 3

Who is on it, and how far along

Every drug ChEMBL records acting on POL, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 7

Approved5

  • Cabotegravir
  • Dolutegravir
  • Bictegravir
  • Raltegravir
  • Elvitegravir

Phase 30

    Phase 22

    • GSK-364735
    • S-1360

    Phase 10

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Human immunodeficiency virus type 1 integrase inhibitor.
      CabotegravirApprovedGilead SciencesSmall moleculeInhibitor62
      DolutegravirApprovedGilead SciencesSmall moleculeInhibitor61
      BictegravirApprovedGilead SciencesSmall moleculeInhibitor40
      RaltegravirApprovedMerck & Co. (MSD)Small moleculeInhibitor10
      ElvitegravirApprovedGilead SciencesSmall moleculeInhibitor7
      GSK-364735Phase 2GSKSmall moleculeInhibitor0
      S-1360Phase 2GSKSmall moleculeInhibitor0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 28 in all, from ClinicalTrials.gov.
      People With Active Viremia Treated With Lenacapavir and Long-Acting Cabotegravir for EffectivenessBictegravir, CabotegravirPhase 1Not yet recruitingNational Institute of Allergy and Infectious Diseases (NIAID)Nov 16, 2026
      Bictegravir Efficacy With 1st INSTI Generation Failure HistoryBictegravir—Not yet recruitingInstitut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'BaNov 12, 2026
      Cohort of Women Living With HIV-1 and Receiving Bictegravir/Emtricitabine/Tenofovir AlafenamideBictegravir—RecruitingCentre de Recherches et d'Etude sur la Pathologie Tropicale et le SidaNov 6, 2026
      Study of BIC/LEN FDC Versus Stable Baseline Regimens in Virologically Suppressed People With HIVBictegravir, Cabotegravir, DolutegravirPhase 4Not yet recruitingGilead SciencesNov 2, 2026
      Multiple Interventions With Distinct Anti-reservoir Activities in People on Antiretroviral TreatmentDolutegravirPhase 2RecruitingFederal University of São PauloOct 29, 2026
      Reaching Persons With HIV Who Are Out of Care Through Expedited Access to Long-Acting Injectable Antiretroviral Therapy - The RELAI StudyCabotegravirPhase 4Not yet recruitingUniversity of North Carolina, Chapel HillOct 26, 2026
      Study on Retention in Care and on Clinical Chracteristics of HIV-infected Women Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIKWO).Bictegravir—Not yet recruitingEnte Ospedaliero Ospedali GallieraOct 6, 2026
      Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus LevelsBictegravirPhase 2RecruitingGilead SciencesSep 25, 2026
      A Study to Investigate Pharmacokinetics (PK), Safety, and Tolerability of VH4367310 in Healthy Adult ParticipantsCabotegravirPhase 1RecruitingViiV HealthcareSep 14, 2026
      A Phase 2b Study Evaluating VH4011499 Capsid Inhibitor Long-Acting Injectable Plus Cabotegravir in Treatment Naïve Adults (CINERGY)Cabotegravir, DolutegravirPhase 2Not yet recruitingViiV HealthcareSep 11, 2026
      An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in AfricaDolutegravirPhase 3Not yet recruitingUniversity College, LondonAug 28, 2026
      Optimization of Antiretroviral Therapy in Patients With AIDS-Related LymphomaBictegravir, CabotegravirNot applicableRecruitingShanghai Public Health Clinical CenterJul 27, 2026
      Efficacy and Safety of ACC017 Tablets Compared With Dolutegravir Sodium Tablets in Treatment-Naïve Adults With Human Immunodeficiency Virus Type 1 (HIV-1)DolutegravirPhase 1 / Phase 2RecruitingJiangsu Aidea Pharmaceutical Group Co., Ltd.Jul 17, 2026
      Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 TreatmentBictegravirPhase 2 / Phase 3RecruitingGilead SciencesJul 16, 2026
      Long-Term Real-World Evidence Study to Evaluate Effectiveness, Persistence, Adherence, Safety and Tolerability of Long-acting Cabotegravir Plus Rilpivirine.Cabotegravir—Active, not recruitingFUNDACIÓN HOSPITAL UNIVERSITARIO INFANTA LEONOR Y DEL HOSPITAL UNIVERSITARIO DEL SURESTEJul 14, 2026
      Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral TherapyCabotegravirPhase 3RecruitingGilead SciencesJul 6, 2026
      Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment RegimensDolutegravirPhase 3RecruitingGilead SciencesJul 6, 2026
      Sleep Outcomes and Multidimensional Sleep Assessment - a Randomized Trial of Dolutegravir- vs Doravirine-based Antiretroviral Therapy in People Living With HIVDolutegravirPhase 4Not yet recruitingUniversity of Witwatersrand, South AfricaJun 29, 2026
      Dolutegravir/Lamivudine in Treatment-Naïve Pregnant WomenDolutegravirPhase 4RecruitingFundación HuéspedJun 1, 2026
      Research on the Psychological Status of Patients With HIV-1 InfectionElvitegravir, Raltegravir—Not yet recruitingShanxi Bethune HospitalJul 23, 2025
      Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1Elvitegravir, RaltegravirPhase 3Active, not recruitingGilead SciencesOct 8, 2024
      Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV VirusesElvitegravir, RaltegravirPhase 2Not yet recruitingANRS, Emerging Infectious DiseasesApr 1, 2024
      A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV TreatmentsElvitegravir, RaltegravirPhase 4RecruitingGilead SciencesMar 29, 2024
      B-free Multistage TrialElvitegravir, RaltegravirPhase 4Enrolling by invitationInsel Gruppe AG, University Hospital BernSep 14, 2023
      Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)Elvitegravir, RaltegravirPhase 2 / Phase 3Active, not recruitingGilead SciencesAug 16, 2022
      Kuwa Free! - Live Free!RaltegravirNot applicableRecruitingUniversity of Alabama at BirminghamSep 16, 2021
      HIV-1 Infected Patients, Phase II Trial, Dual Combination Doravirine/Raltegravir Open LabelRaltegravirPhase 2RecruitingCentre de Recherches et d'Etude sur la Pathologie Tropicale et le SidaAug 14, 2020
      Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIVElvitegravirPhase 2 / Phase 3Active, not recruitingGilead SciencesDec 20, 2013

      Genes and related targets

      Complexes and families that share a gene with this target
      Genes
      POL

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3471, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. ChEMBL and Open Targets

      Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.